This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (12) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Scott, J R Search for Related Content PubMed PubMed Citation Articles by Scott, J R Social Bookmarking                         What's this?

Risks to the children born to mothers with autoimmune diseases

Department of Obstetrics and Gynecology, University of Utah Medical Center,; Obstetrics and Gynecology Editorial Office, 420 Chipeta Way, Suite 100, Salt Lake City, UT 84108, USA.jscott{at}hsc.utah.edu

This article reviews current information regarding the development and long-term effects on children born to women with connective tissue diseases. There are few data on specific effects attributed to the underlying maternal disease, but fetal growth restriction and preterm birth are relatively common. Antenatal use of prednisone as treatment for these disorders appears to be safe, and most children have developed normally. However, there is growing concern that prolonged fetal exposure to other glucocorticoids such as dexamethasone or betamethasone may lead to decreased growth and abnormal neuronal development. Low birth weight is reportedly associated with long-term medical complications such as adult-onset hypertension. Evidence also suggests that immunosuppressive agents taken during pregnancy might predispose the progeny to autoimmune disorders, malignancies and reproductive problems. Further research is warranted to determine that there are no unrecognized long-term risks to the offspring of these women.

Lupus, Vol. 11, No. 10, 655-660 (2002)
DOI: 10.1191/0961203302lu272oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E Rodriguez, J Guevara, A Paez, E Zapata, M. Collados, T. Fortoul, R Lopez-Marure, F Masso, and L. Montano The altered expression of inflammation-related molecules and secretion of IL-6 and IL-8 by HUVEC from newborns with maternal inactive systemic lupus erythematosus is modified by estrogens Lupus, December 1, 2008; 17(12): 1086 - 1095. [Abstract] [PDF]

				M. Biggioggero, M. Borghi, M. Gerosa, L. Trespidi, R. Cimaz, and P. Meroni Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants Lupus, August 1, 2007; 16(8): 651 - 656. [Abstract] [PDF]

				R Cimaz, E Meregalli, M Biggioggero, P Airo, E Danieli, C M Antonioli, M Motta, G Chirico, D Columbrita, M Frassi, et al. Response to tetanus vaccination in infants exposed in utero to immunosuppressants for maternal autoimmune disorders Lupus, February 1, 2007; 16(2): 129 - 132. [Abstract] [PDF]

				J. Dahl, K. -M. Myhr, A. K. Daltveit, J. M. Hoff, and N. E. Gilhus Pregnancy, delivery, and birth outcome in women with multiple sclerosis Neurology, December 27, 2005; 65(12): 1961 - 1963. [Abstract] [Full Text] [PDF]

				R Cimaz Any increased risk of autoimmune disease? Lupus, September 1, 2004; 13(9): 736 - 739. [Abstract] [PDF]